Annovis Bio Inc (ANVS)

$1.99 +0.14 (7.57%)
Market Cap 64.10M
Revenue (ttm) 0.00
Net Income (ttm) -28.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,035,900
Avg Vol 1,249,154
Day's Range N/A - N/A
Shares Out 34.65M
Stochastic %K 35%
Beta 1.27
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
Rmart
Rmart Jun. 5 at 12:55 AM
$ANVS nice action today especially during power hour $SPY $QQQ
1 · Reply
To_De_Moon
To_De_Moon Jun. 4 at 6:53 PM
$ANVS let her run
0 · Reply
Rbrmd
Rbrmd Jun. 4 at 6:35 PM
$ANVS If you look at subgroups of the GLP1 data, a drop in markers(eg NFL, TAU) was required for any improvement. These markers are becoming an important endpoint. They are markers for drug benefit. I look at it this way. Diabetes drug are approved based on glucose level improvement. They can’t ethically require a five year study with a placebo group to measure clinical outcomes. If you have safety and good biomarker data, I suspect that gets you approval. You may think that is crazy, but not really. Cognition improvement is still the goal. However, I don’t think it is necessary at 6 months for approval with good biomarker data. Alzheimer’s families are a politically active and a demanding group.
0 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 11:14 AM
$ANVS The GLP-1 Fallacy: Why Novo's Failure Derisks the P3 Delta A theory is that widespread GLP-1 use among patients could artificially boost the Phase 3 placebo arm, raising the performance floor and shrinking Buntanetap’s success delta. Novo Nordisk’s recent Phase 3 EVOKE failure entirely neutralizes this risk. Because standalone GLP-1s failed to show standalone cognitive efficacy in Alzheimer's, patients in the ANVS placebo arm who are on GLP-1s will likely decline at the standard rate. The placebo floor remains low. However, the active arm tells a different story. In preclinical models, combining Buntanetap with a GLP-1 generated a 6- to 10-fold efficacy spike. If Buntanetap acts as the key that clears toxic proteins, it may unlock the GLP-1’s latent neuroprotective pathways. With the placebo risk eliminated, any synergistic effect in the active arm will could blow the Phase 3 delta wide open. The standalone GLP-1 failure makes Annovis’s combination patents incredibly valuable.
3 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 10:48 AM
$ANVS Triple-Combo Catalyst: Buntanetap + GLP-1 + Viagra Annovis reported that combining Buntanetap with a GLP-1 agonist (Trulicity) or PDE5 inhibitors (Viagra) improved cognition in Alzheimer's mouse models beyond levels observed in healthy controls. Following these compelling results, they filed patents in September 2024 for a triple combination therapy involving Buntanetap, Trulicity, and Viagra. Could we see human data soon? Past AD Trials: The Phase 2/3 AD trial allowed patients to maintain their existing medication regimens. A retrospective analysis isolating patients already taking GLP-1s and PDE5 inhibitors could reveal massive synergistic efficacy. Current OLE: The ongoing Parkinson's Open-Label Extension tracks all real-world concurrent meds. Finding an N=1 case study on this exact triple combo demonstrating explosive improvements is mathematically probable. Validating these new patents with human data would be a massive valuation catalyst.
1 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 10:37 AM
$ANVS The GLP-1 Synergy Catalyst: Let's connect the dots on the Buntanetap + GLP-1 (Trulicity) combination. In preclinical models, Buntanetap paired with dulaglutide didn't just restore cognitive function—it generated a 6- to 10-fold increase in efficacy, boosting memory beyond the levels of healthy controls. Could we see human validation soon? Phase 2/3 AD Retro-Analysis: The completed AD trial allowed patients to stay on existing medications. Because GLP-1s are so widely prescribed, a retrospective analysis isolating patients who took both drugs could reveal hidden, synergistic human efficacy. Current PD OLE: The ongoing 36-month Parkinson's Open-Label Extension is a real-world data goldmine. They track all concurrent meds. An interim data drop highlighting patients naturally taking GLP-1s during the OLE is entirely possible. Annovis already filed patents for this combo. A PR confirming GLP-1 human synergy completely changes valuation metrics. Sleeping giant.
0 · Reply
Bio_Oko
Bio_Oko Jun. 3 at 11:10 PM
$AVXL besides $ANVS and others about which I wrote on my blog can fail long term in affecting dementia. That is the lesson I learned from Alberto Espay.
0 · Reply
Dopamineaddict
Dopamineaddict Jun. 3 at 8:58 PM
$ANVS Optimistic Phase 3 AD Enrollment Modeling: Based on official milestones for the Phase 3 trial , Annovis recently paced at a ~5% enrollment mark bi-weekly. However, back in February and March, they proved capable of a massive ~12.5% bi-weekly rate when all sites fired at once. A member recently posted an email from Maria indicating efforts to expedite the finish line. On May 15, Annovis reported hitting 85% enrollment and officially closed screening to new participants. If they replicate that peak Feb/March rate, sprinkled with some "Maria magic" for a slightly accelerated pace, we might be at 100% enrollment RIGHT NOW. Even if the physical 760th patient was randomized this week, you won't see an immediate PR the exact hour it happens. Data Verification takes time: Clinical ops must securely verify, lock, and log the initial baseline data for the final cohort across all active U.S. sites first. Of course, this is hopeful thinking.
0 · Reply
Phillip_McRevice
Phillip_McRevice Jun. 3 at 5:04 PM
$ANVS this has a ton of insider and institutional buying going on, somebody knows something...
1 · Reply
5DollarNana
5DollarNana Jun. 3 at 2:39 AM
$ANVS what’s happen 2/3/2021 that made this go from $5 to $85 in days?
3 · Reply
Latest News on ANVS
Annovis Bio regains NYSE listing compliance

2026-05-26T15:07:38.000Z - 9 days ago

Annovis Bio regains NYSE listing compliance

Annovis Bio Regains NYSE Listing Compliance

May 26, 2026, 8:00 AM EDT - 9 days ago

Annovis Bio Regains NYSE Listing Compliance

Annovis Bio 7.9M share Spot Secondary priced at $1.90

2026-05-20T12:20:11.000Z - 15 days ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

May 20, 2026, 8:00 AM EDT - 15 days ago

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio announces common stock and warrants offering, no amount given

2026-05-19T20:12:17.000Z - 16 days ago

Annovis Bio announces common stock and warrants offering, no amount given

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 19, 2026, 4:06 PM EDT - 16 days ago

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:30 AM EDT - 20 days ago

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

Annovis Bio Quarterly report: Q1 2026

Annovis Bio Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

Annovis Bio Earnings release: Q1 2026

Annovis Bio Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 21 days ago

Annovis Bio Slides: Corporate presentation

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Annovis Bio Proxy statement: Proxy filing

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Annovis Bio Proxy statement: Proxy filing

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 10, 2026, 8:30 AM EDT - 7 weeks ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Apr 9, 2026, 8:30 AM EDT - 2 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Bio Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Slides: Corporate presentation

Annovis Bio secures U.S. patent for buntanetap

2026-04-02T11:54:03.000Z - 2 months ago

Annovis Bio secures U.S. patent for buntanetap

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Apr 2, 2026, 7:30 AM EDT - 2 months ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Publishes Historical Review of Buntanetap in The Scientist

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Bio Slides: Corporate presentation

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Slides: Corporate presentation

Annovis Bio enters partnership with NeuroRPM

2026-03-19T11:56:46.000Z - 2 months ago

Annovis Bio enters partnership with NeuroRPM

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Mar 19, 2026, 7:30 AM EDT - 2 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:41:50.000Z - 2 months ago

Annovis Bio sees cash runway to 3Q26

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

2026-03-16T11:35:20.000Z - 2 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 16, 2026, 7:30 AM EDT - 2 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Earnings release: Q4 2025

Annovis Bio Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Annovis Bio Annual report: Q4 2025

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Mar 3, 2026, 8:00 AM EST - 3 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

2026-02-12T13:21:18.000Z - 4 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Feb 12, 2026, 8:00 AM EST - 4 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Annovis Bio reports open-label extension study for Parkinson’s disease patients

2025-12-18T21:40:13.000Z - 6 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 18, 2025, 4:35 PM EST - 6 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 16, 2025, 8:00 AM EST - 6 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Dec 3, 2025, 8:00 AM EST - 6 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis announces FDA meeting to discuss PDD program

2025-11-18T14:39:45.000Z - 7 months ago

Annovis announces FDA meeting to discuss PDD program

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 18, 2025, 8:00 AM EST - 7 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

2025-11-17T13:10:41.000Z - 7 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 7 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:11:18.000Z - 7 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

Annovis Bio sees cash runway to 3Q26

2025-11-12T13:10:52.000Z - 7 months ago

Annovis Bio sees cash runway to 3Q26

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 7 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Annovis Bio Earnings release: Q3 2025

Annovis Bio Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Annovis Bio Quarterly report: Q3 2025

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

2025-11-06T13:32:03.000Z - 7 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Nov 6, 2025, 8:00 AM EST - 7 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

2025-10-27T12:05:25.000Z - 7 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 15, 2025, 5:15 PM EDT - 8 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Annovis Bio prices 4M shares at $1.50 in registered direct offering

2025-10-10T12:36:07.000Z - 8 months ago

Annovis Bio prices 4M shares at $1.50 in registered direct offering

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 8 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Annovis Bio announces new results from Phase 2/3 AD study of buntanetap

2025-10-09T11:35:21.000Z - 8 months ago

Annovis Bio announces new results from Phase 2/3 AD study of buntanetap

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Oct 9, 2025, 7:30 AM EDT - 8 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Annovis Bio appoints Guerin as Chief Financial Officer

2025-09-25T11:35:16.000Z - 9 months ago

Annovis Bio appoints Guerin as Chief Financial Officer

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 9 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Bio announces publication of new article in Biomolecules on buntanetap

2025-09-16T11:40:08.000Z - 9 months ago

Annovis Bio announces publication of new article in Biomolecules on buntanetap

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 16, 2025, 7:30 AM EDT - 9 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:00 PM EDT - 9 months ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 10 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 10 months ago

Annovis Bio Quarterly report: Q2 2025

Annovis Bio Earnings release: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 10 months ago

Annovis Bio Earnings release: Q2 2025

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Bio Transcript: Status Update

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 19, 2025, 6:30 AM EDT - 1 year ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025

Annovis Bio Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025

Annovis Bio Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024

Annovis Bio Earnings release: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Rmart
Rmart Jun. 5 at 12:55 AM
$ANVS nice action today especially during power hour $SPY $QQQ
1 · Reply
To_De_Moon
To_De_Moon Jun. 4 at 6:53 PM
$ANVS let her run
0 · Reply
Rbrmd
Rbrmd Jun. 4 at 6:35 PM
$ANVS If you look at subgroups of the GLP1 data, a drop in markers(eg NFL, TAU) was required for any improvement. These markers are becoming an important endpoint. They are markers for drug benefit. I look at it this way. Diabetes drug are approved based on glucose level improvement. They can’t ethically require a five year study with a placebo group to measure clinical outcomes. If you have safety and good biomarker data, I suspect that gets you approval. You may think that is crazy, but not really. Cognition improvement is still the goal. However, I don’t think it is necessary at 6 months for approval with good biomarker data. Alzheimer’s families are a politically active and a demanding group.
0 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 11:14 AM
$ANVS The GLP-1 Fallacy: Why Novo's Failure Derisks the P3 Delta A theory is that widespread GLP-1 use among patients could artificially boost the Phase 3 placebo arm, raising the performance floor and shrinking Buntanetap’s success delta. Novo Nordisk’s recent Phase 3 EVOKE failure entirely neutralizes this risk. Because standalone GLP-1s failed to show standalone cognitive efficacy in Alzheimer's, patients in the ANVS placebo arm who are on GLP-1s will likely decline at the standard rate. The placebo floor remains low. However, the active arm tells a different story. In preclinical models, combining Buntanetap with a GLP-1 generated a 6- to 10-fold efficacy spike. If Buntanetap acts as the key that clears toxic proteins, it may unlock the GLP-1’s latent neuroprotective pathways. With the placebo risk eliminated, any synergistic effect in the active arm will could blow the Phase 3 delta wide open. The standalone GLP-1 failure makes Annovis’s combination patents incredibly valuable.
3 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 10:48 AM
$ANVS Triple-Combo Catalyst: Buntanetap + GLP-1 + Viagra Annovis reported that combining Buntanetap with a GLP-1 agonist (Trulicity) or PDE5 inhibitors (Viagra) improved cognition in Alzheimer's mouse models beyond levels observed in healthy controls. Following these compelling results, they filed patents in September 2024 for a triple combination therapy involving Buntanetap, Trulicity, and Viagra. Could we see human data soon? Past AD Trials: The Phase 2/3 AD trial allowed patients to maintain their existing medication regimens. A retrospective analysis isolating patients already taking GLP-1s and PDE5 inhibitors could reveal massive synergistic efficacy. Current OLE: The ongoing Parkinson's Open-Label Extension tracks all real-world concurrent meds. Finding an N=1 case study on this exact triple combo demonstrating explosive improvements is mathematically probable. Validating these new patents with human data would be a massive valuation catalyst.
1 · Reply
Dopamineaddict
Dopamineaddict Jun. 4 at 10:37 AM
$ANVS The GLP-1 Synergy Catalyst: Let's connect the dots on the Buntanetap + GLP-1 (Trulicity) combination. In preclinical models, Buntanetap paired with dulaglutide didn't just restore cognitive function—it generated a 6- to 10-fold increase in efficacy, boosting memory beyond the levels of healthy controls. Could we see human validation soon? Phase 2/3 AD Retro-Analysis: The completed AD trial allowed patients to stay on existing medications. Because GLP-1s are so widely prescribed, a retrospective analysis isolating patients who took both drugs could reveal hidden, synergistic human efficacy. Current PD OLE: The ongoing 36-month Parkinson's Open-Label Extension is a real-world data goldmine. They track all concurrent meds. An interim data drop highlighting patients naturally taking GLP-1s during the OLE is entirely possible. Annovis already filed patents for this combo. A PR confirming GLP-1 human synergy completely changes valuation metrics. Sleeping giant.
0 · Reply
Bio_Oko
Bio_Oko Jun. 3 at 11:10 PM
$AVXL besides $ANVS and others about which I wrote on my blog can fail long term in affecting dementia. That is the lesson I learned from Alberto Espay.
0 · Reply
Dopamineaddict
Dopamineaddict Jun. 3 at 8:58 PM
$ANVS Optimistic Phase 3 AD Enrollment Modeling: Based on official milestones for the Phase 3 trial , Annovis recently paced at a ~5% enrollment mark bi-weekly. However, back in February and March, they proved capable of a massive ~12.5% bi-weekly rate when all sites fired at once. A member recently posted an email from Maria indicating efforts to expedite the finish line. On May 15, Annovis reported hitting 85% enrollment and officially closed screening to new participants. If they replicate that peak Feb/March rate, sprinkled with some "Maria magic" for a slightly accelerated pace, we might be at 100% enrollment RIGHT NOW. Even if the physical 760th patient was randomized this week, you won't see an immediate PR the exact hour it happens. Data Verification takes time: Clinical ops must securely verify, lock, and log the initial baseline data for the final cohort across all active U.S. sites first. Of course, this is hopeful thinking.
0 · Reply
Phillip_McRevice
Phillip_McRevice Jun. 3 at 5:04 PM
$ANVS this has a ton of insider and institutional buying going on, somebody knows something...
1 · Reply
5DollarNana
5DollarNana Jun. 3 at 2:39 AM
$ANVS what’s happen 2/3/2021 that made this go from $5 to $85 in days?
3 · Reply
RoyalPurp
RoyalPurp Jun. 2 at 9:23 PM
$ANVS Im dumping all my unspent lunch money into this any day its sub-$2. Moves to sub $1? More shares for me. Cant wait for the day, and I have a lot of patience.
0 · Reply
ILikeDaStocks
ILikeDaStocks Jun. 2 at 7:52 PM
$ANVS For anyone curious about the closing of the recent institutional offering, this paragraph was included in the May 20, 2026, Annovis Bio announcement: "Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $15.0 million , excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about May 21, 2026 , subject to the satisfaction of customary closing conditions."
1 · Reply
junkjar291
junkjar291 Jun. 2 at 6:33 PM
$ANVS This is trading like a penny stock on OTC. High volume but up only by 1cent, but when it is red, it goes down by 5-10%, classic OTC trading. Maria need to pull some rabbit to pop this up.
0 · Reply
jimmy18000
jimmy18000 Jun. 2 at 5:24 PM
$ANVS $XBI bright red, and we’re slightly green. We may have found the bottom in the 1.80s area. We should keep going higher through AD full enrollment PR within a month.
0 · Reply
sportee70
sportee70 Jun. 2 at 5:12 PM
$ANVS The only thing that would get me excited is if we doubled the price from here in a 2 to 3-day period. It has been waffling around for the past 4 months now. Be nice to see a breakout to the upside
0 · Reply
zshortcut
zshortcut Jun. 2 at 2:49 PM
$ANVS her day will come.
1 · Reply
Dopamineaddict
Dopamineaddict Jun. 1 at 7:55 PM
$ANVS Reverse engineering the Parkinson's OLE timeline to show why a massive unblinded catalyst is closer than Wall Street thinks. The Math: Target is 500 patients. With 40% (200 patients) enrolled by mid-May, the clinic is moving at ~60 patients/month. Working backward, the first 50 were dosed by late Feb, and the first 100 by late March. Add 3 months for the first clinical data check: 50 patients hit 3 months in late May (being reviewed right now). 100 patients hit 3 months in late June. Is 50 patients enough? Absolutely. A 50-patient cohort at 3 months is highly viable for an initial read on biomarkers and cognitive scores, though 100 is ideal. If the early data holds, Annovis is sitting on a loaded weapon for an interim PR this summer.
4 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Jun. 1 at 7:47 PM
$ANVS "In addition, the translational inhibitor of multiple neurotoxic proteins buntanetap has demonstrated positive outcomes in Phase 3 trials for early-stage PD patients by inhibiting the formation of α-synuclein oligomers and aggregates (NCT05357989)" https://www.sciencedirect.com/science/article/pii/S2213231726002375
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Jun. 1 at 7:47 PM
$ANVS "Many people with Parkinson’s also experience the buildup of other proteins such as Beta-amyloid plaques and Tau tangles, key hallmarks of Alzheimer’s disease. One promising study under way is exploring whether oral therapy buntanetap is safe for long-term use in people with PD. Buntanetap aims to reduce other toxic proteins." https://www.parkinson.org/blog/research/inside-the-science
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Jun. 1 at 7:45 PM
$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 9,824
0 · Reply
ILikeDaStocks
ILikeDaStocks Jun. 1 at 4:34 PM
$ANVS I believe in the eventual success of buntanetap...but the recent institutional offering continues to blow my mind! Who wouldn't pay $1.90 for one common share and one warrant, then unload the common stock in the current range to all buyers...and hold the zero-cost basis six-year warrant until eventual success or failure of buntanetap? NO risk - with possible enormous upside...while shareholders risk hard earned cash with no sweetheart deals! Institutional investors got a...
2 · Reply
ppl_first
ppl_first Jun. 1 at 3:05 PM
$ANVS sunk more at 1.92, thinking “this can’t possibly go any lower”
0 · Reply